Abstract
Hypertension is the most common medical disorder in pregnancy, complicating one in ten pregnancies. Treatment of severely increased blood pressure is widely recommended to reduce the risk for maternal complications. Regimens for the acute treatment of severe hypertension typically include intravenous medications. Although effective, these drugs require venous access and careful fetal monitoring and might not be feasible in busy or low-resource environments. We therefore aimed to compare the efficacy and safety of three oral drugs, labetalol, nifedipine retard, and methyldopa for the management of severe hypertension in pregnancy. In this multicentre, parallel-group, open-label, randomised controlled trial, we compared these oral antihypertensives in two public hospitals in Nagpur, India. Pregnant women were eligible for the trial if they were aged at least 18 years; they were pregnant with fetuses that had reached a gestational age of at least 28 weeks; they required pharmacological blood pressure control for severe hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg); and were able to swallow oral medications. Women were randomly assigned to receive 10 mg oral nifedipine, 200 mg oral labetal...Continue Reading
Citations
Feb 23, 2020·Journal of Perinatal Medicine·Carolina Carvalho MocarzelAsim Kurjak
Mar 7, 2020·Expert Opinion on Pharmacotherapy·Juan Tamargo
Feb 18, 2020·Hypertension·Curt D SigmundYoung S Oh
Jul 3, 2020·BJOG : an International Journal of Obstetrics and Gynaecology·G P GuyB Thilaganathan
May 16, 2020·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jin WangLingzhong Meng
Nov 19, 2019·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Michael GearyElizabeth Stringer
Aug 14, 2020·South African Family Practice : Official Journal of the South African Academy of Family Practice/Primary Care·Jagidesa MoodleyNnabuike C Ngene
Sep 27, 2020·Pregnancy Hypertension·Kim J C VerschuerenMarcus J Rijken
Feb 4, 2021·PloS One·Mariana A CarvalhoAlexandra Benachi
Nov 22, 2020·International Journal of Environmental Research and Public Health·Lisiane Freitas LealAndréa Dâmaso Bertoldi
Feb 27, 2021·Hipertensión y riesgo vascular·A M GhelfiG J Staffieri
Jul 21, 2020·American Journal of Obstetrics and Gynecology·Laura A MageePeter VON Dadelszen
Mar 27, 2021·Pregnancy Hypertension·Christopher M Nash, Nabha Shetty
May 31, 2021·Lancet·Lucy C ChappellStephen Tong
Apr 20, 2021·Journal of the American Heart Association·Sukainah Y Al KhalafAli S Khashan
Jul 31, 2021·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Liona C PoonMoshe Hod
Oct 16, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·Marianne VestgaardElisabeth R Mathiesen
Nov 6, 2021·Expert Opinion on Drug Metabolism & Toxicology·Ian R MulreninCraig R Lee
Oct 18, 2021·American Journal of Obstetrics & Gynecology MFM·Georgios DoulaverisVincenzo Berghella